Oncotargets and Therapy Dovepress

association between chemotactic chemokine ligand 5-403g/a polymorphism and risk of human immunodeficiency virus-1 infection: a meta-analysis Jianglong he 1, Background: The association between chemotactic chemokine ligand 5 (CCL5)-403G/A gene polymorphism and human immunodeficiency virus-1 (HIV-1) infection has been illustrated among several case-control studies, but the conclusions are still inconsistent. Here we performed a meta-analysis to estimate the association. Methods: The published studies based upon the association between CCL5-403G/A poly-morphism and HIV-1 infection were retrieved from PubMed, Embase, and China National Knowledge Infrastructure database. Quantitative synthesis, including pooled odds ratios (ORs) and 95% confidence intervals (CIs), was performed for all genetic models. Results: A total of ten studies consisting of 5,127 subjects were included for this meta-analysis. There was no association found between-403G/A polymorphism and HIV-1 infection in the overall analysis under any genetic models. Further stratified by ethnicity, our analysis showed that-403A/A polymorphism significantly decreased the susceptibility to HIV-1 infection in three models: the dominant model Conclusion: We found that only Asians and Africans with CCL5-403A/A polymorphism could be resistant to HIV-1 infection. However, further studies should be performed to evaluate this association on ethnic basis against control groups consisting of individuals who have once been exposed to HIV-1 but are seronegative.

[1]  Sehrish Naz,et al.  Prognostic Value of Histopathology and Trends in Cervical Cancer , 2022, Pakistan Journal of Medical & Health Sciences.

[2]  Hui Zhang,et al.  High Expression of GRP78 Promotes Invasion and Metastases in Patients with Esophageal Squamous Cell Carcinoma , 2015, Digestive Diseases and Sciences.

[3]  R. Feng,et al.  The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma , 2015, PloS one.

[4]  Jin-Ching Lin,et al.  The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[5]  M. Glennie,et al.  Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study , 2015, Clinical Cancer Research.

[6]  Christian Adam,et al.  CD40‐independent natural killer‐cell help promotes dendritic cell vaccine‐induced T‐cell immunity against endogenous B‐cell lymphoma , 2014, International journal of cancer.

[7]  H. Qin,et al.  Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma , 2014, Medical Oncology.

[8]  Y. Wang,et al.  BTG1 underexpression is an independent prognostic marker in esophageal squamous cell carcinoma , 2014, Tumor Biology.

[9]  Bruce D Cheson,et al.  A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors , 2014, Journal of Hematology & Oncology.

[10]  Hui Li,et al.  Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection. , 2014, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[11]  Yu-qin Pan,et al.  Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients , 2014, Annals of Hematology.

[12]  A. Shenoy,et al.  Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. , 2014, Oral oncology.

[13]  A. Pedersen,et al.  Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials , 2014, Immunopharmacology and immunotoxicology.

[14]  Liang Zhao,et al.  The Cell Surface GRP78 Facilitates the Invasion of Hepatocellular Carcinoma Cells , 2013, BioMed research international.

[15]  K. Goodman,et al.  External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors , 2013, Radiation oncology.

[16]  P. Jänne,et al.  The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.

[17]  Xia He,et al.  Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results. , 2013, Future oncology.

[18]  J. Singer,et al.  Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  S. Altuwaijri,et al.  Intensity modulated radiotherapy of upper abdominal malignancies: dosimetric comparison with 3D conformal radiotherapy and acute toxicity , 2013, Radiation oncology.

[20]  R. Langer,et al.  A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas , 2013, British Journal of Cancer.

[21]  L. Vidal,et al.  Anthracycline-containing regimens for treatment of follicular lymphoma in adults. , 2013, The Cochrane database of systematic reviews.

[22]  J. Blay,et al.  Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. , 2013 .

[23]  C. Gisselbrecht,et al.  The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. , 2013, The oncologist.

[24]  Zongwei Li,et al.  Cell-surface GRP78 facilitates colorectal cancer cell migration and invasion. , 2013, The international journal of biochemistry & cell biology.

[25]  Samuel Hellman,et al.  Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Liu,et al.  Association between Regulated upon Activation, Normal T Cells Expressed and Secreted (RANTES) -28C/G Polymorphism and Susceptibility to HIV-1 Infection: A Meta-Analysis , 2013, PloS one.

[27]  Chaosu Hu,et al.  Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma , 2013, Journal of Cancer Research and Clinical Oncology.

[28]  M. Glennie,et al.  Agonistic CD40 Antibodies and Cancer Therapy , 2013, Clinical Cancer Research.

[29]  D. Drazin,et al.  Multiple intracranial metastases from a gastric gastrointestinal stromal tumor , 2013, Journal of Clinical Neuroscience.

[30]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[31]  J. Singer,et al.  The Novel Anthracenedione, Pixantrone, Lacks Redox Activity and Inhibits Doxorubicinol Formation in Human Myocardium: Insight to Explain the Cardiac Safety of Pixantrone in Doxorubicin-Treated Patients , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[32]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[33]  Y. Miyagi,et al.  [A case of small intestinal stage IV gastrointestinal stromal tumor in which long-term disease control was maintained for more than 10 Years through a multidisciplinary team approach]. , 2012, Gan to kagaku ryoho. Cancer & chemotherapy.

[34]  B. Coiffier,et al.  Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. , 2012, The Lancet. Oncology.

[35]  Huahsi Wu,et al.  Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study. , 2012, European journal of cancer.

[36]  P. Wei,et al.  Silencing of Glucose-Regulated Protein 78 (GRP78) Enhances Cell Migration Through the Upregulation of Vimentin in Hepatocellular Carcinoma Cells , 2012, Annals of Surgical Oncology.

[37]  P. Casali,et al.  Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST) , 2012, Current Treatment Options in Oncology.

[38]  David Goldstein,et al.  Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure , 2012, Clinical Cancer Research.

[39]  A. King,et al.  A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  S. Sanguanrungsirikul,et al.  Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. , 2012, Gynecologic oncology.

[41]  Aki Vehtari,et al.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.

[42]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[43]  J. Eickhoff,et al.  Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry , 2012, BMC Cancer.

[44]  P. Edén,et al.  Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma , 2012, Leukemia & lymphoma.

[45]  S. Lim,et al.  FAK promotes recruitment of talin to nascent adhesions to control cell motility , 2012, The Journal of cell biology.

[46]  D. Dornan,et al.  To respond or not to respond to CD40 agonism: That is the prediction , 2012, Oncoimmunology.

[47]  X. Hao,et al.  Novel immunohistochemical monoclonal antibody against human glucose-regulated protein 78. , 2011, Hybridoma.

[48]  M. Koç,et al.  Gastrointestinal stromal tumor of the rectum with bone and liver metastasis: a case study , 2011, Medical oncology.

[49]  M. Heinrich,et al.  Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.

[50]  J. Fléjou Classification OMS 2010 des tumeurs digestives : la quatrième édition☆ , 2011 .

[51]  L. Brady,et al.  Radiotherapy in the treatment of gastrointestinal stromal tumor , 2011, Rare tumors.

[52]  E. Barbieri,et al.  Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor , 2011, Rare tumors.

[53]  M. Takemura,et al.  Serum interleukin‐18 level is associated with the outcome of patients with diffuse large B‐cell lymphoma treated with CHOP or R‐CHOP regimens , 2011, European journal of haematology.

[54]  S. Groshen,et al.  A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. , 2011, Cancer research.

[55]  A. Bazzocchi,et al.  Three cases of bone metastases in patients with gastrointestinal stromal tumors , 2011, Rare tumors.

[56]  J. Singer,et al.  Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma , 2011, Leukemia & lymphoma.

[57]  A. Lee,et al.  Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. , 2011, International journal of radiation oncology, biology, physics.

[58]  Lei Yao,et al.  CCL3L1 Copy Number Variation and Susceptibility to HIV-1 Infection: A Meta-Analysis , 2010, PloS one.

[59]  G. Tulunay,et al.  Multivariate analysis of prognostic factors in patients with stage IB cervical cancer who underwent radical hysterectomy , 2010 .

[60]  Michael Hummel,et al.  Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. , 2010, Blood.

[61]  Huan-zhang Zhu,et al.  Association between the CCR2-Val64Ile polymorphism and susceptibility to HIV-1 infection: a meta-analysis. , 2010, Molecular medicine reports.

[62]  J. Blay,et al.  Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. , 2010, The Lancet. Oncology.

[63]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  P. Bendahl,et al.  CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2010, Leukemia & lymphoma.

[65]  C. Du,et al.  Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors , 2010, Journal of Cancer Research and Clinical Oncology.

[66]  D. Kim,et al.  Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix , 2010, British Journal of Cancer.

[67]  D. Ennishi,et al.  Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  Robin L. Jones,et al.  Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[69]  Eugene H. Blackstone,et al.  7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction , 2010, Annals of Surgical Oncology.

[70]  M. Frómeta,et al.  Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck , 2010, Cancer biology & therapy.

[71]  Young Tae Kim,et al.  Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy. , 2010, Journal of gynecologic oncology.

[72]  R. Gascoyne,et al.  Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP , 2010, Haematologica.

[73]  H. Kim,et al.  Treatment outcomes and prognostic factors in uterine cervical cancer patients treated with postoperative extended field radiation therapy. , 2009, Journal of gynecologic oncology.

[74]  N. Mehra,et al.  Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. , 2009, Tissue antigens.

[75]  C. Antonescu,et al.  Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. , 2009, The Lancet. Oncology.

[76]  Narasimhan P. Agaram,et al.  Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance , 2009, Clinical Cancer Research.

[77]  Nancy Whiting,et al.  Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  B. Giardina,et al.  New developments in anthracycline-induced cardiotoxicity. , 2009, Current medicinal chemistry.

[79]  S. Pecorelli Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .

[80]  T. Kasamatsu,et al.  Radical hysterectomy for FIGO stage I–IIB adenocarcinoma of the uterine cervix , 2009, British Journal of Cancer.

[81]  C. Greco,et al.  Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report. , 2009, Tumori.

[82]  M. S. Ramakrishnan,et al.  Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin , 2009, mAbs.

[83]  Hao Sun,et al.  Distribution of CCR5-Delta32, CCR2-64I, SDF1-3'A, CX3CR1-249I, and CX3CR1-280M in Chinese populations. , 2008, AIDS research and human retroviruses.

[84]  S. Hee,et al.  Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience. , 2008, International journal of radiation oncology, biology, physics.

[85]  Wiley Interscience,et al.  Association of RANTES −403 G/A, −28 C/G and In1.1 T/C polymorphism with HIV‐1 transmission and progression among North Indians , 2008, Journal of medical virology.

[86]  Hua-Chuan Zheng,et al.  Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. , 2008, Human pathology.

[87]  D. Gaffney,et al.  Incidence, Mortality, and Prognostic Factors of Small Cell Carcinoma of the Cervix , 2008, Obstetrics and gynecology.

[88]  S. S. Kim,et al.  The effects of RANTES/CCR5 promoter polymorphisms on HIV disease progression in HIV‐infected Koreans , 2008, International journal of immunogenetics.

[89]  R. Langer,et al.  Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus , 2008, BMC Cancer.

[90]  C-C Huang,et al.  Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. , 2008, European journal of cancer care.

[91]  J. Nam,et al.  Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  J. Fregnani,et al.  Comparison of biological behavior between early-stage adenocarcinoma and squamous cell carcinoma of the uterine cervix. , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[93]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  S. Groshen,et al.  Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. , 2008, Cancer research.

[95]  D. Moore,et al.  Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group , 2008, Leukemia & lymphoma.

[96]  Thomas C. Chen,et al.  The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. , 2007, Cancer research.

[97]  A. D. Van den Abbeele,et al.  Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors , 2007, Clinical Cancer Research.

[98]  M. Akmansu,et al.  Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate. , 2007, Anti-cancer drugs.

[99]  P. Venugopal,et al.  Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. , 2007, Clinical lymphoma & myeloma.

[100]  Y. Xiong,et al.  Prognostic factors for patients with FIGO Stage-IB cervical squamous cell carcinoma: Does the tumor size (≤ 4 cm or > 4 cm) really matter? , 2007 .

[101]  J. Blay,et al.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  R. Gascoyne,et al.  The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. , 2007, Blood.

[103]  Q. Zhan,et al.  Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma , 2007, Journal of Molecular Medicine.

[104]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  A. Tulpule,et al.  A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma , 2007, Leukemia & lymphoma.

[106]  P. Bendahl,et al.  CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma , 2007, Leukemia & lymphoma.

[107]  K. Charoenkwan,et al.  Clinical outcomes and prognostic factors of node-negative cervical cancer patients with deep stromal invasion or lymphovascular space involvement following radical hysterectomy. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[108]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[110]  H. Joensuu,et al.  Gastrointestinal stromal tumor (GIST) , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[111]  I. Lossos,et al.  Prognostic biomarkers in diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[113]  J. Sham,et al.  Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. , 2006, International journal of radiation oncology, biology, physics.

[114]  M. Lai,et al.  Overexpression of glucose-regulated protein 78 in colon cancer. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[115]  T. Bihani,et al.  Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells , 2006, Oncogene.

[116]  C. Gutiérrez,et al.  Polymorphism of RANTES Chemokine Gene Promoter Is Not Associated With Long-Term Nonprogressive HIV-1 Infection of More Than 16 Years , 2006, Journal of acquired immune deficiency syndromes.

[117]  G. Ahlenstiel,et al.  Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection -- a prospective cross-sectional study. , 2005, World journal of gastroenterology.

[118]  G. Antoch,et al.  Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib , 2005, International journal of cancer.

[119]  B. O'Sullivan,et al.  Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  D. Machin,et al.  Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  K. Ohtomo,et al.  Treatment results and prognostic analysis of radical radiotherapy for locally advanced cancer of the uterine cervix. , 2005, The British journal of radiology.

[122]  M. van Glabbeke,et al.  Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  J. Blay,et al.  Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. , 2005, European journal of cancer.

[124]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[126]  S. Leung,et al.  Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. , 2004, International journal of radiation oncology, biology, physics.

[127]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[128]  S Ma,et al.  Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese. , 2004, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[129]  A. D. Van den Abbeele,et al.  Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  N. Siddiqui,et al.  Depth of cervical stromal invasion as a prognostic factor after radical surgery for early stage cervical cancer. , 2004, Gynecologic oncology.

[131]  J. Koropatnick,et al.  Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  J. Sham,et al.  Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[133]  Shih-hung Huang,et al.  Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. , 2004, Gynecologic oncology.

[134]  M. Kohler,et al.  Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? , 2004, Gynecologic oncology.

[135]  B. Goh,et al.  Epidermal Growth Factor Receptor in Undifferentiated Carcinoma of the Nasopharynx , 2004, The Laryngoscope.

[136]  K. Ang,et al.  CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[137]  T. Poon,et al.  Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study , 2003, Head & neck.

[138]  K. Swenerton,et al.  Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  B. Becker,et al.  How meta-analysis increases statistical power. , 2003, Psychological methods.

[140]  S. Borrego,et al.  Fluorescence resonance energy transfer analysis of the RANTES polymorphisms -403G --> A and -28G --> C: evaluation of both variants as susceptibility factors to HIV type 1 infection in the Spanish population. , 2003, AIDS research and human retroviruses.

[141]  L. Clegg,et al.  Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. , 2003, Gynecologic oncology.

[142]  Chen-Yi Hsu,et al.  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  E. Deconinck,et al.  Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[144]  M. Bamshad,et al.  Signatures of natural selection in the human genome , 2003, Nature Reviews Genetics.

[145]  S. Kvaløy,et al.  Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[146]  C. Fisher,et al.  Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. , 2003, Radiology.

[147]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[148]  N. Sakuragi,et al.  Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy , 2002, Acta obstetricia et gynecologica Scandinavica.

[149]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[150]  John P A Ioannidis,et al.  Commentary: meta-analysis of individual participants' data in genetic epidemiology. , 2002, American journal of epidemiology.

[151]  I. Fidler,et al.  Critical determinants of metastasis. , 2002, Seminars in cancer biology.

[152]  Roy S Herbst,et al.  Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.

[153]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[154]  P. Xia,et al.  Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. , 2001, International journal of radiation oncology, biology, physics.

[155]  O. Kallioniemi,et al.  Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.

[156]  Amy S. Lee,et al.  The glucose-regulated proteins: stress induction and clinical applications. , 2001, Trends in biochemical sciences.

[157]  G. Minotti,et al.  Human Heart Cytosolic Reductases and Anthracycline Cardiotoxicity , 2001, IUBMB life.

[158]  V. Diehl,et al.  Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[159]  M. Hammer,et al.  Global survey of genetic variation in CCR5, RANTES, and MIP-1α: Impact on the epidemiology of the HIV-1 pandemic , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[160]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[161]  C. Crum,et al.  Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. , 2001, Gynecologic oncology.

[162]  B. Yeap,et al.  The effect of surgery and grade on outcome of gastrointestinal stromal tumors. , 2001, Archives of surgery.

[163]  J. Denobile,et al.  CASE REPORT: Adjuvant Radiotherapy for Gastrointestinal Stromal Tumor of the Rectum , 2001, Digestive Diseases and Sciences.

[164]  B. Rollins,et al.  Chemokines and disease , 2001, Nature Immunology.

[165]  J. Smyth,et al.  A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. , 2000, European journal of cancer.

[166]  R. Detels,et al.  Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study , 2000, AIDS.

[167]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[168]  S. O’Brien,et al.  Influence of CCR5 promoter haplotypes on AIDS progression in African–Americans , 2000, AIDS.

[169]  R. V. Vander Heide,et al.  Molecular basis of anthracycline-induced cardiotoxicity and its prevention. , 2000, Molecular genetics and metabolism.

[170]  M. Runge,et al.  Doxorubicin-Induced Cardiomyopathy , 2000 .

[171]  Kenichi Tanaka,et al.  High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. , 2000, Gynecologic oncology.

[172]  U. Wahn,et al.  Atopic Dermatitis Is Associated with a Functional Mutation in the Promoter of the C-C Chemokine RANTES1 , 2000, The Journal of Immunology.

[173]  J. Banchereau,et al.  CD40‐CD40 ligand , 2000, Journal of leukocyte biology.

[174]  P. Debré,et al.  Distribution of HIV-1 disease modifying regulated on activation normal T cell expressed and secreted haplotypes in Asian, African and Caucasian individuals. French ALT and IMMUNOCO Study Group. , 1999, AIDS.

[175]  A. Zelenetz,et al.  Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  P C Levendag,et al.  A three-dimensional CT-based target definition for elective irradiation of the neck. , 1999, International journal of radiation oncology, biology, physics.

[177]  B. Monk,et al.  Young age as a prognostic factor in cervical cancer: results of a population-based study. , 1999, American journal of obstetrics and gynecology.

[178]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[179]  K Fukutake,et al.  Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[180]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  D. Baltimore,et al.  Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[182]  J. Goedert,et al.  Genetic acceleration of AIDS progression by a promoter variant of CCR5. , 1998, Science.

[183]  J. Blay,et al.  Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. , 1998, Blood.

[184]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[185]  M. Mack,et al.  Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.

[186]  J. Cooper,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[187]  L. Roman,et al.  Influence of quantity of lymph-vascular space invasion on the risk of nodal metastases in women with early-stage squamous cancer of the cervix. , 1998, Gynecologic oncology.

[188]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[189]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[190]  J J Goedert,et al.  Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) , 1998, Science.

[191]  P. Lipsky,et al.  Bidirectional regulation of human B cell responses by CD40-CD40 ligand interactions. , 1997, Journal of immunology.

[192]  S. Sheen-Chen,et al.  Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. , 1996, Surgery.

[193]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[194]  G. Pezzoni,et al.  Anthracene-9,10-Diones and Aza Bioisosteres as Antitumor Agents , 1995, Current Medicinal Chemistry.

[195]  J. Chmiel,et al.  Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? , 1995, Cancer.

[196]  M. Hacker,et al.  Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. , 1995, Biochemical pharmacology.

[197]  G. Capranico,et al.  Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. , 1995, Molecular pharmacology.

[198]  M. Hacker,et al.  Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones. , 1995, Cancer letters.

[199]  S. Tucker,et al.  ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[201]  L. Zwelling,et al.  Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. , 1993, Biochemical pharmacology.

[202]  C. Fletcher,et al.  Gastrointestinal stromal tumours: Correlation of immunophenotype with clinicopathological features , 1991, The Journal of pathology.

[203]  P. Smith,et al.  Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. , 1990, Biochemical pharmacology.

[204]  M. Dong,et al.  GRP78 promotes the invasion of pancreatic cancer cells by FAK and JNK , 2014, Molecular and Cellular Biochemistry.

[205]  M. Søgaard,et al.  Prognostic impact of histology in patients with cervical squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[206]  J. Luketich,et al.  Oesophageal carcinoma , 2013, The Lancet.

[207]  R. Shui,et al.  Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix. , 2012, Oncology letters.

[208]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[209]  M. Yan,et al.  Influence of lymph vascular space invasion on prognosis of patients with early-stage cervical squamous cell carcinoma. , 2010, Chinese journal of cancer.

[210]  Ji-Hong Liu,et al.  Risk factors and prognosis of IB-IIB cervical carcinoma with common iliac lymph node metastasis. , 2010, Chinese journal of cancer.

[211]  Huijuan Song,et al.  Grp78 promotes the invasion of hepatocellular carcinoma. , 2010, BMC cancer.

[212]  B. Hallberg,et al.  c-Kit--a hematopoietic cell essential receptor tyrosine kinase. , 2007, The international journal of biochemistry & cell biology.

[213]  L. Dawson,et al.  Upper abdominal malignancies: intensity-modulated radiation therapy. , 2007, Frontiers of radiation therapy and oncology.

[214]  M. Zelefsky,et al.  Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. , 2006, International journal of radiation oncology, biology, physics.

[215]  S. O’Brien,et al.  Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. , 2006, The Journal of infectious diseases.

[216]  R. K. Sachdeva,et al.  Gene Polymorphisms in CCR5, CCR2, CX3CR1, SDF-1 and RANTES in Exposed but Uninfected Partners of HIV-1 Infected Individuals in North India , 2006, Journal of Clinical Immunology.

[217]  E. Glatstein Gastrointestinal Stromal Tumor: New Nodule-Within-a-Mass Pattern of Recurrence After Partial Response to Imatinib Mesylate , 2006 .

[218]  W. Hop,et al.  Prognostic factors in adenocarcinoma of the uterine cervix. , 2004, Gynecologic oncology.

[219]  C. Gisselbrecht,et al.  Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. , 2003, Haematologica.

[220]  R. Wenham,et al.  Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. , 2002, Gynecologic oncology.

[221]  E. Raymond,et al.  A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[222]  A. Davis,et al.  Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database , 2001 .

[223]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[224]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[225]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[226]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[227]  J. Gribben,et al.  Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. , 1998, Blood.

[228]  L. Sobin,et al.  Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. , 1997, Archives of pathology & laboratory medicine.

[229]  Amy S. Lee,et al.  The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications. , 1994, Critical reviews in eukaryotic gene expression.

[230]  A. Bird Immunology of HIV Infection , 1992, Immunology and Medicine Series.

[231]  S. Jagannath,et al.  Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). , 1988, Blood.

[232]  M. Serdar,et al.  Oncotargets and Therapy , 2022 .